Table 8.
Compilation of the most relevant publications leveraging GHTO resources.
| Fist Author | Title | Data Used |
|---|---|---|
| Western, D51 | Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and informs causal proteins for Alzheimer’s disease. |
Array-Based Genomics CSF proteomics |
| Wang, C55 | Unique genetic architecture of CSF and brain metabolites pinpoints the novel targets for the traits of human wellness. |
Array-Based Genomics CSF & Brain Metabolomics |
| Ali, M69 | Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s disease. | CSF Proteomics |
| Do, AN70 | CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer’s disease. | CSF Proteomics |
| Wang, L71 | Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease. |
Array-Based Genomics CSF proteomics |
| Cisterna-García, A30 | Cell-free RNA signatures predict Alzheimer’s disease. | Plasma acellular Transcriptomics |
| Timsina, J72 | Harmonization of CSF and imaging biomarkers in Alzheimer’s disease: Need and practical applications for genetics studies and preclinical classification. | CSF Proteomics |
| Brase, L47 | Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. | Brain Single Nuclei Transcriptomics |
| Oh, HS73 | Organ aging signatures in the plasma proteome track health and disease. | Plasma Proteomics |
| Wang, D74 | Frequency of Variants in Mendelian Alzheimer’s Disease Genes within the Alzheimer’s Disease Sequencing Project (ADSP). | Whole Genome Sequencing |
| Gorijala, P75 | Alzheimer’s polygenic risk scores are associated with cognitive phenotypes in Down syndrome. |
Array-Based Genomics PRS Calculations |
| Phillips, B76 | Proteome wide association studies of LRRK2 variants identify novel causal and druggable proteins for Parkinson’s disease. |
Array-Based Genomics CSF proteomics |
| Sung, YJ48 | Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease. | Brain, Plasma, & CSF Proteomics |
| Panyard, DJ77 | Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer’s disease. |
Proteomics Metabolomics |
| Bradley, J78 | Genetic architecture of plasma Alzheimer disease biomarkers. |
Array-Based Genomics Plasma proteomics |
| Ali, M79 | Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease. | Array-Based Genomics |
| Yang, C80 | Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes. |
Array-Based Genomics Brain & CSF proteomics |
| Holstege, H81 | Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease. | Whole Exome Sequencing |
| Li, F82 | Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease. | Brain Bulk Transcriptomics |
| Yang, C14 | Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. | Brain, Plasma, & CSF Proteomics |
| Dube, U12 | An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. | Brain Bulk Transcriptomics |
| Li, Z83 | The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. | Brain Bulk Transcriptomics |
| Deming, Y84 | The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. | Array-Based Genomics |
| Del-Aguila, JL85 | TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. | Brain Bulk Transcriptomics |
| Fernandez, MV16 | Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. |
Whole Genome Sequencing Whole Exome Sequencing |
| Cruchaga, C10 | Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. |
Array-Based Genomics PRS Calculations |
| Fernandez, MV18 | Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. |
Whole Genome Sequencing Whole Exome Sequencing |